Clinical Trial Update: A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder [Phase 3]

View source ↗

Summary

Phase 3 trial results for mirabegron (YM178) in adults with overactive bladder; the study completed and results were posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overactive Bladder

Drugs mentioned

• Mirabegron (mirabegron)

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Urinary Bladder, Overactive | Phase 3 | Status: COMPLETED | Results posted: 2012-10-17